Research location
Carmel
Indiana, United States
Advertisement
Research activity in Carmel
Indiana, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 119 trials and 120 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Carmel
119 linked trials · page 2 of 3Omega3 Wound Fish Skin Graft in the Treatment of DFUsNCT04133493 · 2019-07-31 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)NCT03811002 · 2019-07-26 · 1 site observation
ACTIVE_NOT_RECRUITING
PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate CancerNCT03429244 · 2019-04-15 · 1 site observation
COMPLETED
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast CancerNCT03598257 · 2019-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated ArthralgiasNCT03384095 · 2018-12-14 · 1 site observation
WITHDRAWN
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerNCT03488693 · 2018-10-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerNCT03373760 · 2017-11-30 · 1 site observation
COMPLETED
Improving the Recovery and Outcome Every Day After the ICUNCT03095417 · 2017-09-25 · 1 site observation
COMPLETED
Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United StatesNCT03197688 · 2017-08-03 · 1 site observation
COMPLETED
Understanding and Predicting Breast Cancer Events After TreatmentNCT02791581 · 2017-07-21 · 1 site observation
ACTIVE_NOT_RECRUITING
iMETX (Individualized Metabolic RX): a Pilot StudyNCT03158519 · 2017-05-15 · 1 site observation
COMPLETED
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03 · 1 site observation
COMPLETED
Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNCT02834013 · 2017-01-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNCT02954874 · 2017-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyNCT02927249 · 2017-01-06 · 1 site observation
TERMINATED
Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast CancerNCT02681120 · 2016-10-07 · 1 site observation
COMPLETED
Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active SurveillanceNCT02799745 · 2016-06-09 · 1 site observation
COMPLETED
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02785952 · 2015-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Accu-Chek® CONNECT at School (CATS) Pediatric StudyNCT02609633 · 2015-12-28 · 1 site observation
COMPLETED
Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant ChemotherapyNCT02595372 · 2015-11-12 · 1 site observation
COMPLETED
Finding the Patient's Voice Diabetes Prevention ProgramsNCT02700503 · 2015-11-01 · 1 site observation
COMPLETED
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyNCT02445391 · 2015-10-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)NCT02398188 · 2015-04-09 · 1 site observation
COMPLETED
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02154490 · 2014-07-08 · 1 site observation
COMPLETED
MRI and Mammography Before Surgery in Patients With Stage I-II Breast CancerNCT01805076 · 2014-05-21 · 1 site observation
COMPLETED
Advancing Diabetes Management in Adolescents Using Health Information TechnologyNCT02115555 · 2014-05-01 · 1 site observation
COMPLETED
OPsumit USers RegistryNCT02126943 · 2014-04-30 · 1 site observation
COMPLETED
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticNCT02115282 · 2014-03-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryNCT01953588 · 2014-02-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With ChemotherapyNCT01901094 · 2014-02-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult SubjectsNCT01994109 · 2013-11-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerNCT02003924 · 2013-10-31 · 1 site observation
COMPLETED
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate CancerNCT01946204 · 2013-10-14 · 1 site observation
ACTIVE_NOT_RECRUITING
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerNCT01674140 · 2013-09-12 · 1 site observation
ACTIVE_NOT_RECRUITING
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionNCT01560637 · 2013-09-11 · 1 site observation
COMPLETED
Pre-Operative Radiation and Veliparib for Breast CancerNCT01618357 · 2013-07-22 · 1 site observation
COMPLETED
Beraprost-314d Added-on to Tyvaso® (BEAT)NCT01908699 · 2013-05-31 · 1 site observation
COMPLETED
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung CancerNCT01642251 · 2012-09-28 · 1 site observation
COMPLETED
Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrixNCT01729286 · 2012-09-01 · 1 site observation
TERMINATED
Treatment for Persistently Fatigued Cancer Survivors: A Randomized Controlled Trial With Biomarker ResponseNCT01919853 · 2012-09-01 · 1 site observation
COMPLETED
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast CancerNCT01556243 · 2012-07-01 · 1 site observation
COMPLETED
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral MonotherapyNCT01560624 · 2012-06-26 · 1 site observation
COMPLETED
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung CancerNCT01362400 · 2011-05-01 · 1 site observation
COMPLETED
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerNCT01272037 · 2011-02-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerNCT01244191 · 2011-01-11 · 1 site observation
TERMINATED
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH TherapiesNCT01266265 · 2010-12-01 · 1 site observation
COMPLETED
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)NCT01178073 · 2010-10-01 · 1 site observation
COMPLETED
ACT-293987 in Pulmonary Arterial HypertensionNCT01112306 · 2010-07-07 · 1 site observation
COMPLETED
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue AdministrationNCT01161563 · 2010-07-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.